TigerResearch/tigerbot-earning-plugin huggingface dataset:
项目|期末余额|||期初余额||
|账面余额|存货跌价准备/合同履约成本减值准备|账面价值|账面余额|存货跌价准备/合同履约成本减值准备|账面价值
在产品|578,068,969.40|1,006,821.80|577,062,147.60|533,720,411.24|2,339,029.57|531,381,381.67
低值易耗品及其他|5,821,399.69||5,821,399.69|1,148,408.16||1,148,408.16
原材料及包装物|891,665,423.90|838,316.65|890,827,107.25|679,804,664.44|2,413,483.94|677,391,180.50
产成品及库存商品|1,970,083,415.28|23,108,016.73|1,946,975,398.55|1,936,496,913.21|19,775,432.93|1,916,721,480.28
合计|3,445,639,208.27|24,953,155.18|3,420,686,053.09|3,151,170,397.05|24,527,946.44|3,126,642,450.61
项目|期初余额|本期增加金额||本期减少金额||期末余额
||计提|其他|转回或转销|其他|
在产品|2,339,029.57|148,778.00|||1,480,985.77|1,006,821.80
库存商品||||||
原材料及包装物|2,413,483.94|224,159.88||1,799,327.17||838,316.65
产成品及库存商品|19,775,432.93|16,204,082.96||10,877,154.08|1,994,345.08|23,108,016.73
合计|24,527,946.44|16,577,020.84||12,676,481.25|3,475,330.85|24,953,155.18
项目|期末余额|期初余额
待抵扣税费|103,509,485.31|117,788,861.45
预缴所得税|229,686,778.05|3,467,186.72
预缴土地使用税||1,857,965.53
其他|28,088.86|271,030.89
合计|333,224,352.22|123,385,044.59
项目|期末余额|||期初余额|||折现率区间
|账面余额|坏账准备|账面价值|账面余额|坏账准备|账面价值|
融资租赁款|||||||
其中:未实现融资收益|||||||
分期收款销售商品|41,385,982.93||41,385,982.93|63,908,568.23||63,908,568.23|
分期收款提供劳务|||||||
按组合计提坏账准备的应收账款|385,887,907.92|11,576,637.24|374,311,270.68|687,388,671.19|20,621,660.14|666,767,011.05|
其中:组合1:未逾期的长期医院保证金|385,633,468.36|11,569,004.05|374,064,464.31|426,394,098.31|12,791,822.95|413,602,275.36|
组合2:长期权益的往来款|254,439.56|7,633.19|246,806.37|260,994,572.88|7,829,837.19|253,164,735.69|
合计|427,273,890.85|11,576,637.24|415,697,253.61|751,297,239.42|20,621,660.14|730,675,579.28|/
类别|期末余额|||期初余额||
|账面余额|预期信用损失率(%)|坏账准备|账面余额|预期信用损失率(%)|坏账准备
医院保证金|385,633,468.36|3.00|11,569,004.05|426,394,098.31|3.00|12,791,822.95
合计|385,633,468.36|3.00|11,569,004.05|426,394,098.31|3.00|12,791,822.95
类别|期末余额|||期初余额||
|账面余额|预期信用损失率(%)|坏账准备|账面余额|预期信用损失率(%)|坏账准备
武汉珂美立德生物医药有限公司||||260,424,063.00|3.00|7,812,721.89
人福医药恩施有限公司人福健康大药房旗舰店|254,439.56|3.00|7,633.19|570,509.88|3.00|17,115.30
合计|254,439.56|3.00|7,633.19|260,994,572.88|3.00|7,829,837.19
类别|期末余额|||期初余额||
|账面余额|预期信用损失率(%)|坏账准备|账面余额|预期信用损失率(%)|坏账准备
分期收款销售商品|41,385,982.93|||63,908,568.23||
合计|41,385,982.93|||63,908,568.23||
被投资单位|期初余额|本期增减变动||||||||期末余额|减值准备期末余额
||追加投资|减少投资|权益法下确认的投资损益|其他综合收益调整|其他权益变动|宣告发放现金股利或利润|计提减值准备|其他||
一、合营企业|||||||||||
人福医药恩施有限公司人福健康大药房红江店|345,052.02|||57,516.04|||-45,052.23|||357,515.83|
人福医药恩施有限公司人福健康大药房旗舰店||||-49,908.65|||||49,908.65||
小计|345,052.02|||7,607.39|||-45,052.23||49,908.65|357,515.83|
二、联营企业|||||||||||
天风证券股份有限公司|2,356,450,300.84||-2,332,661,127.64|4,862,748.09|-10,400,590.73|-10,460,495.40|-4,873,786.65||-2,917,048.51||
武汉新创创业投资有限公司|18,553,484.70|||132,997.90|-668,052.00|||||18,018,430.60|
中煤科工金融租赁股份有限公司|471,105,318.99|||-4,132,719.84||||||466,972,599.15|
瑞多仕(武汉)制药有限公司|3,197,793.23|||157,602.36||||||3,355,395.59|
呼伦贝尔松鹿制药有限有限公司|44,778,662.09|||-524,290.28||-523,787.82||||43,730,583.99|
北京玛诺生物制药股份有限公司|36,736,693.99|||25,972.44||||||36,762,666.43|
海南湖槟投资有限公司|39,817,049.80|||-284,916.25||||||39,532,133.55|
人福瀚源(上海)实业发展股份有限公司|4,090,326.65|||-642,876.80||||||3,447,449.85|
 Agic-Humanwell Blue Ridge (US) Limited|572,463,279.36||-617,472,159.01|10,745,663.48|34,263,216.17||||||
 Lifestyles Healthcare Pte. Ltd.|671,415,313.06||-758,315,281.76|10,920,250.69|75,979,718.01||||||
杭州观苏生物技术有限公司|29,006,972.76|||-931,553.43||||||28,075,419.33|
苏州含光微纳科技有限公司|16,851,001.04|||-3,243,977.34|-25,218.57|2,764,512.88||||16,346,318.01|
湖北英特搏智能机器有限公司|7,624,675.78|||-764,550.36||||||6,860,125.42|
吉凯(武汉)医学科技有限公司|17,773,202.03|||218,584.24||||||17,991,786.27|
武汉杰士邦卫生用品有限公司||394,177,081.66||5,967,620.70|-11,477,084.63|||||388,667,617.73|
小计|4,289,864,074.32|394,177,081.66|-3,708,448,568.41|22,506,555.60|87,671,988.25|-8,219,770.34|-4,873,786.65||-2,917,048.51|1,069,760,525.92|
合计|4,290,209,126.34|394,177,081.66|-3,708,448,568.41|22,514,162.99|87,671,988.25|-8,219,770.34|-4,918,838.88||-2,867,139.86|1,070,118,041.75|
项目|期末余额|期初余额
华泰保险集团股份有限公司|1,025,502,035.50|984,888,093.50
武汉璟泓科技股份有限公司|23,700,000.00|33,540,000.00
医多多(武汉)医学信息科技有限责任公司||262,316.36
重庆云信医疗科技有限公司|3,359,463.92|3,370,299.09
武汉先路医药科技股份有限公司|10,800,000.00|10,800,000.00
武汉博沃生物科技有限公司|24,014,240.28|27,162,024.99
江苏耀海生物制药有限公司|6,403,093.39|5,489,905.28
天风证券股份有限公司|379,443,380.19|
武汉融晶实业投资有限公司|150,000,000.00|
合计|1,623,222,213.28|1,065,512,639.22
项目|期末余额|期初余额
固定资产|5,265,160,060.65|5,623,887,988.22
固定资产清理||
合计|5,265,160,060.65|5,623,887,988.22
项目|房屋及建筑物|机器设备|运输工具|其他设备|合计
一、账面原值:|||||
1.期初余额|3,812,438,391.16|3,285,746,705.56|103,329,594.46|1,010,454,963.19|8,211,969,654.37
2.本期增加金额|214,269,035.95|214,946,931.45|11,665,519.13|115,322,743.37|556,204,229.90
(1)购置|133,090,117.91|83,113,434.31|11,534,894.59|102,537,927.60|330,276,374.41
(2)在建工程转入|32,904,541.59|88,467,586.78||3,616,814.97|124,988,943.34
(3)企业合并增加|38,514,408.12|32,032,863.46||8,469,283.21|79,016,554.79
(4)外币折算差异|9,759,968.33|11,333,046.90|130,624.54|698,717.59|21,922,357.36
3.本期减少金额|285,844,239.29|237,821,246.19|14,889,209.01|84,734,890.94|623,289,585.43
(1)处置或报废|9,664,847.38|68,221,455.45|10,456,155.43|16,914,834.68|105,257,292.94
(2)企业合并减少|276,179,391.91|169,599,790.74|4,433,053.58|67,820,056.26|518,032,292.49
4.期末余额|3,740,863,187.82|3,262,872,390.82|100,105,904.58|1,041,042,815.62|8,144,884,298.84
二、累计折旧|||||
1.期初余额|607,139,277.17|1,353,775,168.29|52,365,101.43|482,815,596.29|2,496,095,143.18
2.本期增加金额|111,926,721.76|331,703,032.64|10,753,588.83|109,697,046.19|564,080,389.42
(1)计提|110,564,038.52|327,464,386.46|10,665,450.21|109,474,645.65|558,168,520.84
(2)外币折算差异|1,362,683.24|4,238,646.18|88,138.62|222,400.54|5,911,868.58
3.本期减少金额|82,096,198.14|117,484,831.39|13,473,353.56|57,717,831.07|270,772,214.16
(1)处置或报废|1,246,890.63|47,509,080.50|10,086,988.92|13,670,204.56|72,513,164.61
(2)企业合并减少|80,849,307.51|69,975,750.89|3,386,364.64|44,047,626.51|198,259,049.55
4.期末余额|636,969,800.79|1,567,993,369.54|49,645,336.70|534,794,811.41|2,789,403,318.44
三、减值准备|||||
1.期初余额|81,614,939.05|10,328,899.32||42,684.60|91,986,522.97
2.本期增加金额||||58.64|58.64
(1)外币折算差异||||58.64|58.64
(1)计提|||||
3.本期减少金额||1,654,739.13||10,922.73|1,665,661.86
(1)处置或报废||1,067,643.12|||1,067,643.12
(2)企业合并减少||587,096.01||10,922.73|598,018.74
4.期末余额|81,614,939.05|8,674,160.19||31,820.51|90,320,919.75
四、账面价值|||||
1.期末账面价值|3,022,278,447.98|1,686,204,861.09|50,460,567.88|506,216,183.70|5,265,160,060.65
2.期初账面价值|3,123,684,174.94|1,921,642,637.95|50,964,493.03|527,596,682.30|5,623,887,988.22
项目|账面价值|未办妥产权证书的原因
房屋建筑物|324,750,738.01|正在办理中
合计|324,750,738.01|
项目|期末余额|期初余额
在建工程|2,742,482,826.16|1,182,888,025.14
工程物资|25,308,373.74|2,293,513.23
合计|2,767,791,199.90|1,185,181,538.37
项目|期末余额|||期初余额||
|账面余额|减值准备|账面价值|账面余额|减值准备|账面价值
宜昌人福白洋生产基地原料药一阶段项目|461,048,481.59||461,048,481.59|221,548,898.66||221,548,898.66
宜昌人福小容量注射制剂国际标准生产基地|391,856,998.87||391,856,998.87|262,730,520.92||262,730,520.92
宜昌人福国际药物研究中心|335,289,818.70||335,289,818.70|189,503,349.55||189,503,349.55
宜昌人福国际高端原料药生产基地|320,034,107.95||320,034,107.95|166,564,615.51||166,564,615.51
湖北葛店人福医药国际高端新型特色原料药产业化生产基地建设项目|279,048,605.53||279,048,605.53|17,791,277.50||17,791,277.50
宜昌人福全球总部基地辅助项目|269,318,869.48||269,318,869.48|92,742,279.25||92,742,279.25
宜昌人福冻干车间|142,453,254.49||142,453,254.49|||
武汉光谷生物医药创新中心|118,945,926.92||118,945,926.92|40,982,919.92||40,982,919.92
宜昌人福行政办公楼|76,164,228.03||76,164,228.03|||
北京医疗科技园区|67,489,492.43||67,489,492.43|||
宜昌人福高端复杂制剂车间|57,943,362.87||57,943,362.87|||
湖北葛店人福药用辅料有限责任公司新型药用辅料生产基地|56,886,769.14||56,886,769.14|12,007,660.51||12,007,660.51
新疆维药一亿盒维吾尔药生产基地|44,937,398.46||44,937,398.46|17,827,469.02||17,827,469.02
钟祥人福中医院国医馆|34,067,516.59||34,067,516.59|34,067,516.59||34,067,516.59
宜昌人福白洋生产基地原料药二阶段项目|22,591,982.06||22,591,982.06|||
宜昌人福原料药二期项目|12,837,473.29||12,837,473.29|||
宜昌人福口服制剂出口基地|3,355,831.39||3,355,831.39|28,859,280.96||28,859,280.96
三峡制药科技园项目||||55,463,792.07||55,463,792.07
其他|48,212,708.37||48,212,708.37|42,798,444.68||42,798,444.68
合计|2,742,482,826.16||2,742,482,826.16|1,182,888,025.14||1,182,888,025.14
项目名称|预算数|期初余额|本期增加金额|本期转入固定资产金额|本期其他减少金额|期末余额|工程累计投入占预算比例(%)|工程进度|利息资本化累计金额|其中:本期利息资本化金额|本期利息资本化率(%)|资金来源
宜昌人福白洋生产基地原料药一阶段项目|499,000,000.00|221,548,898.66|239,499,582.93|||461,048,481.59|92.39||23,382,013.87|12,899,999.98|4.35|自有资金、金融机构贷款
宜昌人福小容量注射制剂国际标准生产基地|496,000,000.00|262,730,520.92|129,126,477.95|||391,856,998.87|79|||||自有资金、募集资金
宜昌人福国际药物研究中心|481,000,000.00|189,503,349.55|145,786,469.15|||335,289,818.70|69.71|||||自有资金
宜昌人福国际高端原料药生产基地|390,000,000.00|166,564,615.51|153,469,492.44|||320,034,107.95|82.06|||||自有资金
湖北葛店人福医药国际高端新型特色原料药产业化生产基地建设项目|1,500,000,000.00|17,791,277.50|261,257,328.03|||279,048,605.53|18.6||4,314,045.50|4,314,045.50|4.90|自有资金、金融机构贷款
宜昌人福全球总部基地辅助项目|336,000,000.00|92,742,279.25|176,576,590.23|||269,318,869.48|80.15|||||自有资金
宜昌人福冻干车间|455,000,000.00||142,453,254.49|||142,453,254.49|31.32|||||自有资金
武汉光谷生物医药创新中心|170,000,000.00|40,982,919.92|77,963,007.00|||118,945,926.92|69.97||2,614,226.11|423,158.88|4.42|自有资金、金融机构贷款
宜昌人福行政办公楼|482,000,000.00||76,164,228.03|||76,164,228.03|15.81|||||自有资金
北京医疗科技园区|249,000,000.00|590,062.47|66,899,429.96|||67,489,492.43|27.1|||||自有资金
宜昌人福高端复杂制剂车间|274,000,000.00||57,943,362.87|||57,943,362.87|21.15|||||自有资金
新疆维药一亿盒维吾尔药生产基地|160,000,000.00|17,827,469.02|27,109,929.44|||44,937,398.46|28.09||584,843.35|584,843.35|4.8|自有资金、金融机构贷款
宜昌人福白洋生产基地原料药二阶段项目|220,000,000.00||22,591,982.06|||22,591,982.06|10.26|||||自有资金
宜昌人福原料药二期项目|399,000,000.00||12,837,473.29|||12,837,473.29|3.22|||||自有资金
合计|6,111,000,000.00|1,010,281,392.80|1,589,678,607.87|||2,599,960,000.67|||30,895,128.83|18,222,047.71||
项目|期末余额|||期初余额||
|账面余额|减值准备|账面价值|账面余额|减值准备|账面价值
专用设备|24,402,417.16||24,402,417.16|945,611.38||945,611.38
专用材料|905,956.58||905,956.58|1,347,901.85||1,347,901.85
合计|25,308,373.74||25,308,373.74|2,293,513.23||2,293,513.23
项目|房屋及建筑物|合计
一、账面原值||
1.期初余额|102,061,232.09|102,061,232.09
2.本期增加金额|22,994,330.14|22,994,330.14
(1)新增租赁|22,110,542.65|22,110,542.65
(2)外币报表折算|883,787.49|883,787.49
3.本期减少金额|14,262,631.70|14,262,631.70
(1)退租|14,262,631.70|14,262,631.70
4.期末余额|110,792,930.53|110,792,930.53
二、累计折旧||
1.期初余额|20,091,672.80|20,091,672.80
2.本期增加金额|25,122,985.77|25,122,985.77
(1)计提|24,966,946.80|24,966,946.80
(2)外币报表折算|156,038.97|156,038.97
3.本期减少金额|5,518,943.61|5,518,943.61
(1)处置||
(2)退租|5,518,943.61|5,518,943.61
4.期末余额|39,695,714.96|39,695,714.96
三、减值准备||
1.期初余额||
2.本期增加金额||
(1)计提||
3.本期减少金额||
(1)处置||
4.期末余额||
四、账面价值||
1.期末账面价值|71,097,215.57|71,097,215.57
2.期初账面价值|81,969,559.29|81,969,559.29
项目|土地使用权|专利权|非专利技术|特许经营权|药品经营许可权|专有技术|医院举办权|其他|合计
一、账面原值|||||||||
1.期初余额|1,154,004,108.37|||1,711,614.29|650,027,971.51|513,371,034.40|177,731,876.22|96,670,689.58|2,593,517,294.37
2.本期增加金额|56,269,420.21||||63,521,377.94|417,951,580.73||87,772,961.05|625,515,339.93
(1)购置|23,438,799.10||||8,118,717.80|174,992,989.36||29,021,773.94|235,572,280.20
(2)内部研发||||||235,798,127.16|||235,798,127.16
(3)企业合并增加|32,830,621.11|||||5,159,932.73||58,751,187.11|96,741,740.95
(4)外币报表折算|||||55,402,660.14|2,000,531.48|||57,403,191.62
3.本期减少金额|260,745,110.81|||862,182.29|11,287,155.74|26,554,707.34||1,936,450.05|301,385,606.23
(1)处置|160,362,163.65||||11,287,155.74|9,445,384.43||158,681.11|181,253,384.93
(2)企业合并减少|99,882,039.80|||862,182.29||17,109,322.91||46,153.85|117,899,698.85
(3)外币报表折算|500,907.36|||||||1 ,731,615.09|2,232,522.45
4.期末余额|949,528,417.77|||849,432.00|702,262,193.71|904,767,907.79|177,731,876.22|182,507,200.58|2,917,647,028.07
二、累计摊销|||||||||
1.期初余额|150,289,274.75|||1,580,517.30|307,554,574.48|127,894,021.99||44,472,118.94|631,790,507.46
2.本期增加金额|48,729,856.90|||80,487.00|55,544,431.51|76,111,250.68||11,346,511.56|191,812,537.65
(1)计提|48,729,759.76|||80,487.00|29,784,394.86|75,170,940.45||11,150,488.49|164,916,070.56
(2)外币报表折算|97.14||||25,760,036.65|940,310.23||196,023.07|26,896,467.09
3.本期减少金额|59,596,524.86|||811,572.30|6,532,301.56|24,310,215.38||73,730.58|91,324,344.68
(1)处置|30,539,273.68||||6,532,301.56|7,220,563.75||27,576.73|44,319,715.72
(2)企业合并减少|29,057,251.18|||811,572.30||17,089,651.63||46,153.85|47,004,628.96
4.期末余额|139,422,606.79|||849,432.00|356,566,704.43|179,695,057.29||55,744,899.92|732,278,700.43
三、减值准备|||||||||
1.期初余额|15,778,247.27||||200,899,560.08||||216,677,807.35
2.本期增加金额|||||18,556,354.74||||18,556,354.74
(1)计提|||||||||
(1)外币报表折算|||||18,556,354.74||||18,556,354.74
3.本期减少金额|||||||||
(1)处置|||||||||
4.期末余额|15,778,247.27||||219,455,914.82||||235,234,162.09
四、账面价值|||||||||
1.期末账面价值|794,327,563.71||||126,239,574.46|725,072,850.50|177,731,876.22|126,762,300.66|1,950,134,165.55
2.期初账面价值|987,936,586.35|||131,096.99|141,573,836.95|385,477,012.41|177,731,876.22|52,198,570.64|1,745,048,979.56
本期末通过公司内部研发形成的无形资产占无形资产余额的比例8.08%
项目|期初余额|本期增加金额||本期减少金额||期末余额
||内部开发支出|其他|确认为无形资产|转入当期损益|
药品研发支出|908,075,317.46|1,133,976,652.49||235,798,127.16|1,003,260,407.74|802,993,435.05
合计|908,075,317.46|1,133,976,652.49||235,798,127.16|1,003,260,407.74|802,993,435.05
被投资单位名称或形成商誉的事项|期初余额|本期增加||本期减少|期末余额
||企业合并形成的|外币报表折算差额|处置|
 Epic Pharma, LLC|2,627,118,628.81||242,657,302.02||2,869,775,930.83
 Epic Re Holdco, LLC|80,599,901.17||7,444,716.94||88,044,618.11
北京巴瑞医疗器械有限公司|623,423,961.10||||623,423,961.10
宜昌三峡普诺丁生物制药有限公司|128,469,606.97||||128,469,606.97
宜昌三峡制药有限公司|36,287,181.92||||36,287,181.92
杭州诺嘉医疗设备有限公司|84,289,103.73||||84,289,103.73
湖北生物医药产业技术研究院有限公司|45,877,920.66||||45,877,920.66
江苏尤里卡生物科技有限公司|32,183,799.39||||32,183,799.39
湖北朗德医疗科技有限公司|28,174,331.44||||28,174,331.44
湖北人福康博瑞医药有限公司|26,000,000.00||||26,000,000.00
 PURACAP PHARMACEU TICAL LLC|23,135,849.96||||23,135,849.96
杭州加尔铁进出口有限公司|20,753,313.44||||20,753,313.44
湖北人福成田药业有限公司|12,347,149.97||||12,347,149.97
湖北人福医药贸易有限公司|6,000,000.00||||6,000,000.00
湖北人福长江医药有限公司|6,000,000.00||||6,000,000.00
湖北人福诺生药业有限责任公司|5,150,263.35||||5,150,263.35
武汉康乐药业股份有限公司|4,241,699.73||||4,241,699.73
乌鲁木齐市和信中荣商贸有限公司|3,199,051.72||||3,199,051.72
宜昌天仁药业有限责任公司|1,965,421.33||||1,965,421.33
湖北人福医药集团有限公司|1,590,773.27||||1,590,773.27
人福医药荆州有限公司|1,200,533.96||||1,200,533.96
人福医药恩施有限公司|226,812.96||||226,812.96
上海天阖投资合伙企业(有限合伙)|62,867,856.97|||62,867,856.97|
杭州福斯特药业有限公司|53,253,906.89|||53,253,906.89|
河南百年康鑫药业有限公司|10,220,922.76|||10,220,922.76|
合计|3,924,577,991.50||250,102,018.96|126,342,686.62|4,048,337,323.84
被投资单位名称或形成商誉的事项|期初余额|本期增加||本期减少|期末余额
||计提|外币报表折算差额|处置|
 Epic Pharma, LLC|2,612,452,811.46||241,302,674.32||2,853,755,485.78
 Epic Re Holdco, LLC|80,149,954.44||7,403,157.01||87,553,111.45
杭州诺嘉医疗设备有限公司|35,588,908.91||||35,588,908.91
湖北朗德医疗科技有限公司||28,174,331.44|||28,174,331.44
 PURACAP PHARMACEU TICAL LLC|23,135,849.96||||23,135,849.96
杭州加尔铁进出口有限公司|20,753,313.44||||20,753,313.44
湖北人福康博瑞医药有限公司|9,418,933.93|7,155,861.64|||16,574,795.57
武汉康乐药业股份有限公司|4,241,699.73||||4,241,699.73
乌鲁木齐市和信中荣商贸有限公司|3,199,051.72||||3,199,051.72
湖北人福医药贸易有限公司|1,267,100.00||||1,267,100.00
杭州福斯特药业有限公司|38,216,555.24|||38,216,555.24|
河南百年康鑫药业有限公司|10,220,922.76|||10,220,922.76|
合计|2,838,645,101.59|35,330,193.08|248,705,831.33|48,437,478.00|3,074,243,648.00
项目| Epic Pharma, LLC 与Epic Re Holdco, LLC|北京巴瑞医疗器械有限公司|宜昌三峡制药有限公司与宜昌三峡普诺丁生物制药有限公司|杭州诺嘉医疗设备有限公司|湖北生物医药产业技术研究院有限公司
商誉账面余额1|295,782.05|62,342.40|16,475.68|8,428.91|4,587.79
商誉减值准备余额2|294,130.86|||3,558.89|
商誉的账面价值3=1-2|1,651.19|62,342.40|16,475.68|4,870.02|4,587.79
未确认归属于少数股东权益的商誉价值4||15,585.60||1,217.51|682.50
调整后整体商誉的账面价值5=4+3|1,651.19|77,928.00|16,475.68|6,087.53|5,270.29
资产组的账面价值6|27,731.52|17,052.06|86,992.37|15,839.65|6,804.75
包含整体商誉的资产组的账面价值7=5+6|29,382.71|94,980.06|103,468.05|21,927.18|12,075.04
资产组预计未来现金流量的现值(可回收金额)8|36,340.03|98,367.22|104,795.45|22,127.49|16,353.04
商誉减值损失(大于0 时)且不大于包含未确认归属于少数股东权益的商誉价值9=7-8|||||
母公司持股比例(%)10|||||
合并账面商誉减值损失1○1=9*10|||||
商誉减值测试重要假设、依据及参数 I.重要假设及依据
1假设被评估单位持续性经营,被评估资产按管理层对资产组预计的用途和使用的方式、规模、频度、环境等情况继续使用,或者在有所改变的基础上使用,相应确定评估方法、参数和依据;
单位|关键参数||||
|预测期|预测期增长率|稳定期增长率|利润率|折现率
 Epic Pharma, LLC 与 Epic Re Holdco, LLC|2023 年-2027 年(后续为稳定期)|注1|持平|根据预测的收入、成本、费用等计算|11.84%
北京巴瑞医疗器械有限公司|2023 年-2027 年(后续为稳定期)|注2|持平|根据预测的收入、成本、费用等计算|10.50%
宜昌三峡制药有限公司与宜昌三峡普诺丁生物制药有限公司|注3以资产的公允价值减去处置费用后的净额来测算||||
杭州诺嘉医疗设备有限公司|2023 年-2027 年(后续为稳定期)|注4|持平|根据预测的收入、成本、费用等计算|10.58%
湖北生物医药产业技术研究院有限公司|注5以资产的公允价值减去处置费用后的净额来测算||||
注:1Epic Pharma, LLC 与Epic Re Holdco, LLC2023 年-2027 年预计的销售收入增长率为-1.13%、1.96%、1.00%、1.00%、1.00%;
2北京巴瑞医疗器械有限公司2023 年-2027 年预计的销售收入增长率为8.88%、8.38%、8.63%、8.38%、8.38%;
3宜昌三峡制药有限公司与宜昌三峡普诺丁生物制药有限公司商誉的可回收金额以资产的公允价值减去处置费用后的净额来测算;
4杭州诺嘉医疗设备有限公司2023 年-2027 年预计的销售收入增长率为3.85%、3.85%、3.85%、3.85%、3.85%;
5湖北生物医药产业技术研究院有限公司商誉的可回收金额以资产的公允价值减去处置费用后的净额来测算。
本期商誉变动情况详见本节“八、合并范围的变更”。
项目|期初余额|本期增加金额|本期摊销金额|其他减少金额|期末余额
 GMP 及GSP 认证|3,385,321.26||1,052,007.70||2,333,313.56
装修费及其他|40,080,897.98|11,821,065.24|14,130,600.31|3,108,618.16|34,662,744.75
合计|43,466,219.24|11,821,065.24|15,182,608.01|3,108,618.16|36,996,058.31
项目|期末余额||期初余额|
|可抵扣暂时性差异|递延所得税资产|可抵扣暂时性差异|递延所得税资产
资产减值准备|182,900,375.89|36,251,459.08|183,654,159.90|34,553,739.94
内部交易未实现利润|7,437,641.63|1,115,646.24|4,634,870.50|695,230.58
可抵扣亏损||||
政府补助|108,193,465.77|16,229,019.87|94,432,651.81|14,164,897.78
预提未结算费用及其他|35,226,430.87|7,774,865.87|37,064,345.13|8,820,466.89
经营性租赁|2,234,601.52|542,729.19|2,747,941.37|686,447.27
公允价值变动|10,844,088.65|1,660,616.80|283,847.88|42,577.18
合计|346,836,604.33|63,574,337.05|322,817,816.59|58,963,359.64
项目|期末余额||期初余额|
|应纳税暂时性差异|递延所得税负债|应纳税暂时性差异|递延所得税负债
其他权益工具投资公允价值变动||||
固定资产加速折旧|1,500,841,873.35|225,424,491.24|516,635,443.22|77,688,487.44
收购资产评估增值|327,653,507.04|49,148,026.05|332,319,248.29|49,847,887.24
公允价值变动|566,658,471.97|137,500,607.90|493,949,050.79|119,749,341.77
合计|2,395,153,852.36|412,073,125.19|1,342,903,742.30|247,285,716.45
项目|期末余额|期初余额
可抵扣暂时性差异|238,649,750.28|341,096,636.54
可抵扣亏损|3,268,349,467.54|3,654,914,231.74
合计|3,506,999,217.82|3,996,010,868.28
年份|期末金额|期初金额|备注
2022 年||289,326,825.83|
2023 年|170,280,801.83|207,362,392.57|
2024 年|365,724,695.20|1,139,546,383.31|
2025 年|967,880,808.37|975,240,378.07|
2026 年|1,001,275,724.28|1,043,438,251.96|
2027 年|763,187,437.86||
合计|3,268,349,467.54|3,654,914,231.74|/
项目|期末余额|||期初余额||
|账面余额|减值准备|账面价值|账面余额|减值准备|账面价值
预付土地款及其他|3,663,901.22||3,663,901.22|5,000,000.00||5,000,000.00
预付专有技术|51,909,378.50||51,909,378.50|||
预付工程款|30,103,778.28||30,103,778.28|137,236,910.39||137,236,910.39
预付设备款|223,589,640.49||223,589,640.49|295,325,858.59||295,325,858.59
预付资产购买款|1,244,967,883.00||1,244,967,883.00|||
合计|1,554,234,581.49||1,554,234,581.49|437,562,768.98||437,562,768.98
项目|期末余额|期初余额
质押借款|2,230,749,086.39|1,765,705,415.74
抵押借款|775,000,000.00|629,000,000.00
保证借款|3,121,310,000.00|3,972,718,302.40
信用借款|444,922,800.00|517,922,800.00
短期借款应付利息|16,825,106.30|13,288,654.72
合计|6,588,806,992.69|6,898,635,172.86
1本期用于抵押借款的抵押物情况见本节“七、81、所有权或使用权受到限制的资产”;
2存在子公司以资产抵质押做第一担保方式,同时本公司提供信用保证的双重担保时,按第一担保方式分类;
3期末保证借款中,公司及子公司之间以担保方式,取得的借款金额为274,631.00 万元;武汉当代科技产业集团股份有限公司为本公司借款提供担保,取得的借款金额为37,500.00 万元;4期末质押借款中,公司以持有的子公司股权质押,取得的借款为103,500.00 万元;公司以持有天风证券13,000.00 万股股权质押,取得的短期借款金额为20,000.00 万元,公司以持有的医院应收账款、货币资金、商业票据、保证金等质押取得的借款金额为99,574.91 万元。
项目|期初余额|本期增加|本期减少|期末余额
交易性金融负债||||
其中:||||
外汇掉期||1,106,035.00||1,106,035.00
合计||1,106,035.00||1,106,035.00
种类|期末余额|期初余额
商业承兑汇票||
银行承兑汇票|635,431,591.72|612,254,706.14
合计|635,431,591.72|612,254,706.14
项目|期末余额|期初余额
1 年以内(含1 年)|2,575,961,306.37|1,854,120,079.76
1 年以上|237,625,657.76|220,709,338.93
合计|2,813,586,964.13|2,074,829,418.69
项目|期末余额|未偿还或结转的原因
非关联方|14,119,385.49|未到结算期
非关联方|8,676,986.44|未到结算期
非关联方|8,665,000.99|未到结算期
非关联方|5,784,137.04|未到结算期
非关联方|5,519,790.96|未到结算期
合计|42,765,300.92|/
项目|期末余额|期初余额
1 年以内(含1 年)|1,500,000.00|313,650,610.65
1 年以上|308,350,760.79|700,150.14
合计|309,850,760.79|314,350,760.79
项目|期末余额|未偿还或结转的原因
非关联方|307,650,610.65|未到结算期
合计|307,650,610.65|/
项目|期末余额|期初余额
1 年以内(含1 年)|416,182,585.58|259,292,382.04
1 年以上|182,717,281.41|93,043,013.27
合计|598,899,866.99|352,335,395.31
项目|期初余额|本期增加|本期减少|期末余额
一、短期薪酬|96,584,984.20|2,528,330,782.48|2,340,133,754.59|284,782,012.09
二、离职后福利-设定提存计划|483,059.56|166,787,754.35|164,320,871.66|2,949,942.25
三、辞退福利||1,058,585.28|1,058,585.28|
四、一年内到期的其他福利||||
合计|97,068,043.76|2,696,177,122.11|2,505,513,211.53|287,731,954.34
项目|期初余额|本期增加|本期减少|期末余额
一、工资、奖金、津贴和补贴|83,273,968.64|2,244,961,456.71|2,061,568,568.07|266,666,857.28
二、职工福利费|596,757.00|89,967,873.11|89,600,050.11|964,580.00
三、社会保险费|2,224,067.35|90,264,358.08|91,052,647.25|1,435,778.18
其中:医疗保险费|2,209,645.55|84,935,777.74|85,763,388.71|1,382,034.58
工伤保险费|13,070.54|4,915,434.08|4,877,115.40|51,389.22
生育保险费|1,351.26|413,146.26|412,143.14|2,354.38
四、住房公积金|65,075.47|69,915,564.51|69,966,436.18|14,203.80
五、工会经费和职工教育经费|7,211,268.12|32,927,302.27|27,860,535.50|12,278,034.89
六、短期带薪缺勤|3,213,847.62|294,227.80|85,517.48|3,422,557.94
七、短期利润分享计划||||
合计|96,584,984.20|2,528,330,782.48|2,340,133,754.59|284,782,012.09
项目|期初余额|本期增加|本期减少|期末余额
1、基本养老保险|416,066.73|160,214,000.07|157,773,631.82|2,856,434.98
2、失业保险费|66,992.83|6,573,754.28|6,547,239.84|93,507.27
3、企业年金缴费||||
合计|483,059.56|166,787,754.35|164,320,871.66|2,949,942.25
项目|期末余额|期初余额
增值税|103,433,946.45|198,747,704.32
消费税||
营业税||
企业所得税|107,371,657.36|268,309,215.92
个人所得税|7,942,259.38|8,602,363.13
城市维护建设税|4,481,577.43|8,894,088.75
房产税|7,402,484.10|7,872,774.98
土地使用税|1,897,533.18|3,018,058.46
教育费附加|2,716,734.31|4,271,792.32
其他税费|58,556,958.09|55,166,170.20
合计|293,803,150.30|554,882,168.08
项目|期末余额|期初余额
应付利息||
应付股利|78,577,105.03|8,239,809.87
其他应付款|1,711,710,252.83|1,862,505,951.92
合计|1,790,287,357.86|1,870,745,761.79
项目|期末余额|期初余额
普通股股利|78,577,105.03|8,239,809.87
合计|78,577,105.03|8,239,809.87
其他说明,包括重要的超过1年未支付的应付股利,应披露未支付原因:暂时不需要支付。
项目|期末余额|期初余额
保证金|72,384,146.39|71,602,427.86
押金|4,616,389.68|4,759,872.62
应付收购股权款|52,352,200.00|160,650.00
应付期间费用|533,678,683.79|591,541,164.31
往来款|867,462,727.77|901,049,543.98
股权激励款|181,216,105.20|293,392,293.15
合计|1,711,710,252.83|1,862,505,951.92
项目|期末余额|未偿还或结转的原因
关联方|261,810,000.00|未到结算期
非关联方|41,462,478.55|未到结算期
非关联方|7,714,102.57|未到结算期
非关联方|5,622,599.19|未到结算期
非关联方|5,586,750.00|未到结算期
合计|322,195,930.31|/
项目|期末余额|期初余额
1 年内到期的长期借款|1,419,522,008.36|1,273,171,760.95
1 年内到期的应付债券||1,100,000,000.00
1 年内到期的长期应付款|315,084,702.23|318,273,647.17
1 年内到期的租赁负债|20,536,349.27|17,854,214.93
一年内到期的非流动负债利息|274,833.32|21,418,723.57
合计|1,755,417,893.18|2,730,718,346.62
项目|期末余额|期初余额
短期应付债券||
应付退货款||
待转销项税|67,821,282.14|49,792,618.68
合计|67,821,282.14|49,792,618.68
项目|期末余额|期初余额
质押借款|176,280,000.00|982,960,000.00
抵押借款|614,186,702.23|341,569,241.08
保证借款|1,039,000,000.00|1,128,500,000.00
信用借款||336,398,100.00
长期借款应付利息|23,947,305.44|10,887,807.12
合计|1,853,414,007.67|2,800,315,148.20
2存在公司及子公司以资产抵质押做第一担保方式,同时本公司提供信用保证的双重担保时,按第一担保方式分类;
3期末保证借款中,公司及子公司之间以担保方式,取得的长期借款金额为83,900.00 万元,一年内到期的长期借款为20,750.00 万元;武汉当代科技产业集团股份有限公司为本公司借款提供担保,取得的长期借款金额为20,000.00 万元,一年内到期的长期借款39,500.00 万元;
4期末质押借款中,公司以持有的武汉人福康诚医药有限公司100%的股权作为质押,取得借款4,300.00 万元;公司以医院应收账款为质押,取得长期借款13,328.00 万元,一年内到期的长期借款金额为1,668.00 万元;公司以持有天风证券13,000.00 万股股权质押,取得的一年内到期的长期借款金额为29,400.00 万元。
质押借款借款利率区间为1.2%-5.145%,抵押借款借款利率区间为1.2%-5.5%,保证借款借款利率区间为3.75%-6%,信用借款借款利率区间为1.7855%-4.8%。
项目|期末余额|期初余额
公司债券||450,000,000.00
应付利息||24,647,671.23
合计||474,647,671.23
债券名称|面值|发行日期|债券期限|发行金额|期初余额|本期发行|按面值计提利息|溢折价摊销|本期偿还|期末余额
20 人福01|100|2020 年3 月12 日|2+1 年|450,000,000.00|450,000,000.00||5,952,328.77||450,000,000.00|
合计|/|/|/|450,000,000.00|450,000,000.00||5,952,328.77||450,000,000.00|
项目|期末余额|期初余额
租赁付款额|75,972,506.62|87,690,172.59
减:未确认融资费用|-5,436,228.00|-8,170,778.12
减:一年内到期的租赁负债|-20,536,349.27|-17,854,214.93
合计|49,999,929.35|61,665,179.54
项目|期末余额|期初余额
长期应付款|5,000,000.00|20,734,773.93
专项应付款|16,380,000.00|23,539,092.92
合计|21,380,000.00|44,273,866.85
项目|期末余额|期初余额
融资租赁|5,000,000.00|20,734,773.93
合计|5,000,000.00|20,734,773.93
单位|期限|实际利率(%)|融资租赁金额|累计未确认融资费用|期初余额
广州万宝融资租赁有限公司|36 个月|8.68|30,000,000.00|4,557,000.00|25,000,000.00
科学城(广州)融资租赁有限公司|24 个月|6.70|11,000,000.00||4,950,000.00
科学城(广州)融资租赁有限公司|24 个月|7.77|10,000,000.00|951,805.56|8,993,695.73
欧力士融资租赁(中|24 个月|6.07|11,293,980.78|781,890.95|7,262,999.61
国)有限公司|||||
佛山海晟金融租赁股份有限公司|12 个月|8.10|10,000,000.00|649,116.69|10,000,000.00
武汉光谷融资租赁有限公司|30 个月|4.11|50,000,000.00|14,384,166.69|58,929,746.80
武汉光谷融资租赁有限公司|24 个月|4.10|184,090,000.00|52,875,761.61|223,871,978.96
减:一年内到期的长期应付款|||||318,273,647.17
合计|||306,383,980.78|74,199,741.50|20,734,773.93
单位|本期未确认融资费用|本期归还租金|期末余额|借款条件
广州万宝融资租赁有限公司|1,953,000.00|11,953,000.00|15,000,000.00|售后回租
科学城(广州)融资租赁有限公司||4,950,000.00||售后回租
科学城(广州)融资租赁有限公司|553,579.33|5,048,625.00|4,498,650.06|售后回租
欧力士融资租赁(中国)有限公司|305,475.86|6,332,351.60|1,236,123.87|售后回租
佛山海晟金融租赁股份有限公司||10,000,000.00||售后回租
武汉光谷融资租赁有限公司|3,454,419.89||62,384,166.69|售后回租
武汉光谷融资租赁有限公司|13,093,782.65||236,965,761.61|售后回租
减:一年内到期的长期应付款|||315,084,702.23|
合计|19,360,257.73|38,283,976.60|5,000,000.00|
项目|期初余额|本期增加|本期减少|期末余额|形成原因
人才专项资金|759,092.92||379,092.92|380,000.00|
搬迁入园补助资金|22,780,000.00||6,780,000.00|16,000,000.00|
合计|23,539,092.92||7,159,092.92|16,380,000.00|/